TABLE 2.
Gastroprotective effect of different gastric lesion inducers in mouse.
| Models | Treatments (p.o.) | Dose (mg/kg) | ULI | Inhibition (%) |
|---|---|---|---|---|
| NSAIDs (piroxicam) | 5% Tween 80 | — | 118.6 ± 5.2 | |
| Ranitidine | 50 | 56.8 ± 7.3*** | 52 | |
| (-)-Carveol | 25 | 101.4 ± 5.9*** | 14 | |
| 50 | 83.0 ± 4.3*** | 30 | ||
| 100 | 48.6 ± 2.9*** | 59 | ||
| 200 | 47.2 ± 3.2*** | 60 | ||
| Stress (cold/restraint) | 5% Tween 80 | — | 195.7 ± 10.6 | |
| Ranitidine | 50 | 94.0 ± 9.5*** | 52 | |
| (-)-Carveol | 25 | 159.7 ± 6.1*** | 18 | |
| 50 | 111.7 ± 7.0*** | 43 | ||
| 100 | 76.7 ± 10.7*** | 61 | ||
| 200 | 76.0 ± 12.4*** | 62 |
Results are expressed as mean ± SD. One-way analysis of variance (ANOVA): followed by Dunnett’s and Tukey’s test was performed using the software Graph Pad Prism. ***p < 0.001 compared to the control group (5% Tween 80). (n = 8/per group). ULI, Ulcerative Lesion Index.